Who are Equillium, Inc.'s main suppliers?

Equillium, Inc. (EQ) key suppliers include: ARIAGEN-INC, Sanofi, Sanofi. View the full supplier network at chainsifter.com/chain/EQ.

Who are Equillium, Inc.'s major customers?

Equillium, Inc. (EQ) key customers include: COLLABORATION-PARTNER, Sanofi, Sanofi. View the full customer network at chainsifter.com/chain/EQ.

What sector is Equillium, Inc. in?

Equillium, Inc. (EQ) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

EQ Supply Chain: Equillium, Inc. Supplier List & 9 Relationships

3Suppliers

3Customers

3Debt Items

20Related Chains

Equillium, Inc. Suppliers

Ticker	Name	Confidence	Evidence
ARIAGEN-INC	ARIAGEN-INC	90%	In October 2024, we acquired Ariagen, Inc., or Ariagen, to obtain exclusive, worldwide rights to EQ504, a potent and selective AhR modulator.
SNYNF	Sanofi	72%	rotagonist Therapeutics, Inc., Sanofi SA, Takeda Pharmaceuticals, Teva Pharmaceuticals, Topas Therapeutics GmbH, and Zedira GmbH. Sales and Marketing Given our stage of development, we have not yet e…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from EQ graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from EQ graph: Reciprocal relationship from SNYNF gr…

Equillium, Inc. Customers

Ticker	Name	Confidence	Evidence
COLLABORATION-PARTNER	COLLABORATION-PARTNER	90%	From 2022 to 2024, we generated revenue from an upfront payment and development funding related to an asset purchase agreement with a collaboration partner.
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from EQ graph: rotagonist Therapeutics, Inc., Sanofi SA, Takeda Pharmaceuticals, Teva Pharmaceuticals, Topas Therapeutics GmbH, and Z…
SNYNF	Sanofi	72%	rotagonist Therapeutics, Inc., Sanofi SA, Takeda Pharmaceuticals, Teva Pharmaceuticals, Topas Therapeutics GmbH, and Zedira GmbH. Sales and Marketing Given our stage of development, we have not yet e…

Equillium, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
EQ-DEBT-9340	Warrants outstanding: 266000	90%	xbrl warrant detail from xbrl 2019-12-31.
EQ-DEBT-9341	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2018-12-31.
EQ-DEBT	Debt stack $692,000	90%	Market cache reports total debt of $692,000.

Equillium, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Equillium, Inc..

Equillium, Inc. Ownership

Holder	Name	Confidence	Evidence
EQ-OWNER-JANUS-HENDERSON-GROUP-PLC	JANUS HENDERSON GROUP PLC	90%	13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 51 tracked holders.

Equillium, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
SNYNF	Sanofi	100.00	1	['customer', 'supplier']
ALXO	ALX Oncology Holdings Inc.	50.00	2
CLDX	Celldex Therapeutics, Inc.	50.00	2
CTMX	CytomX Therapeutics, Inc.	50.00	2
ANL	Adlai Nortye Ltd.	50.00	2
ANRO	Alto Neuroscience, Inc.	50.00	2
CRVS	Corvus Pharmaceuticals, Inc.	50.00	2
BIOA	BioAge Labs, Inc.	50.00	2
CYTK	Cytokinetics, Incorporated	50.00	2
CBIO	Crescent Biopharma, Inc.	50.00	2
RXRX	Recursion Pharmaceuticals, Inc.	50.00	2
CCEP	Coca-Cola Europacific Partners PLC	50.00	2
DSGN	Design Therapeutics, Inc.	50.00	2
AZN	AstraZeneca PLC	50.00	2
CYTOF	Altamira Therapeutics Ltd.	50.00	2
DBVTF	DBV TECHNOLOGIES	50.00	2
EDIT	Editas Medicine, Inc.	50.00	2
FULC	Fulcrum Therapeutics, Inc.	50.00	2
LGND	Ligand Pharmaceuticals Incorporated	50.00	2
WHWK	Whitehawk Therapeutics, Inc.	50.00	2

Equillium, Inc. Supply Chain